What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Insights
Briefings written for compounding pharmacy, med-aesthetic, distributor, and research-lab procurement teams. Updated monthly.
A pharmacy-QA checklist for GLP-1 peptide API qualification: COA, HPLC, MS, endotoxin, bioburden, water, counter-ion, stability, and supplier traceability.
Published May 26, 2026 · 5 min read
Read briefing
Sourcing GuideA pharmacy procurement template for telling a peptide supplier the country, pathway, route, documentation scope, and release tests needed before quote stage.
Published May 26, 2026 · 5 min read
Read briefing
QualityA practical first-lot review checklist for pharmacy QA teams qualifying peptide API before recurring supply.
Published May 26, 2026 · 5 min read
Read briefing
RegulatoryA buyer's briefing on BPC-157, TB-500, KPV, MOTs-C, Emideltide, Semax, and Epitalon, what changes, what doesn't, and how to prepare your sourcing pipeline.
Published May 16, 2026 · 6 min read
Read briefing
Sourcing GuideA buyer-side checklist for selecting a BPC-157 supplier: COA depth, sequence verification, regulatory awareness, and how to test before you scale.
Published May 12, 2026 · 5 min read
Read briefing
ComparisonSide-by-side sourcing notes for Semaglutide, Tirzepatide, and Retatrutide: receptor class, documentation depth, analytical risk, lead time, and buyer-fit questions.
Published May 8, 2026 · 8 min read
Read briefing
Sourcing GuideHow procurement teams should qualify Cagrilintide and CagriSema lots: amylin-analog identity, blend-ratio evidence, COA scope, HPLC/MS, stability, and route-specific testing.
Published May 28, 2026 · 6 min read
Read briefing
QualityWhat every line on a Certificate of Analysis means, which fields actually matter for your application, and how to spot a doctored document.
Published May 2, 2026 · 7 min read
Read briefing
RegulatorySide-by-side on the two FDA-regulated compounding pathways, eligibility, supplier qualification, documentation depth, and which path your peptide ships under.
Published May 19, 2026 · 8 min read
Read briefing
ComparisonThe two most-requested repair peptides compared on sequence, mechanism, analytics, and why the Wolverine Blend combines them rather than dosing them sequentially.
Published May 15, 2026 · 9 min read
Read briefing
ComparisonFour next-generation GLP-1-family peptides compared on receptor profile, clinical status, supply economics, and how to pick the right molecule for your research or compounding pipeline.
Published May 12, 2026 · 11 min read
Read briefing
Industry InsightWhy the canonical GH-axis blend works mechanistically, how the components differ, what ratio matters in practice, and the analytics that distinguish a clean blend from a sloppy one.
Published May 10, 2026 · 10 min read
Read briefing
Sourcing GuideWhat to do (and not do) when incorporating GHK-Cu copper tripeptide into a finished cosmetic product, stability, pH, chelator compatibility, and the analytical checks that confirm the active is still active.
Published May 6, 2026 · 8 min read
Read briefing
QualityWhat the counter-ion is, why most synthetic peptides ship as either acetate or TFA salt, how to tell which you have, and why downstream pharmaceutical and assay work strongly prefers acetate.
Published May 4, 2026 · 6 min read
Read briefing
Sourcing GuideSix concrete checks that distinguish a serious China-based peptide manufacturer from a paper-only middleman, documentation depth, analytical transparency, regulatory awareness, and supply continuity.
Published May 14, 2026 · 10 min read
Read briefing
Sourcing GuideSix stages of the OEM peptide workflow, RFQ, NDA and quote, sample synthesis, formulation/packaging development, commercial production, and recurring-order operations. Timeline, deliverables, and what each stage actually involves.
Published May 13, 2026 · 11 min read
Read briefing
Industry InsightWhy volume peptide pricing varies 10× across suppliers for the same molecule, what drives the cost stack, how MOQ and lead time interact with price, and what break points actually matter in your procurement strategy.
Published May 18, 2026 · 12 min read
Read briefing
QualityWhat endotoxin contamination is, why it confounds peptide research and clinical readouts, how the LAL test works, what specifications to ask for on your COA, and which peptides need the test most.
Published May 16, 2026 · 9 min read
Read briefing
Sourcing GuideMed-spa peptide procurement is different from compounding pharmacy or research-lab buying. This guide covers the workhorse SKUs, the OEM finished-product pathway, INCI naming and CPNP notification, and the regulatory landscape specific to aesthetic medicine.
Published May 14, 2026 · 10 min read
Read briefing
RegulatoryFDA's evolving position on compounded Tirzepatide, the October 2024 removal from the drug-shortage list, the late-2024 court rulings, and what compounding-pharmacy buyers need to know about sourcing and dispensing today.
Published May 11, 2026 · 10 min read
Read briefing
Industry InsightHow Fmoc-strategy SPPS actually works, why cycle yield matters more than total yield, where common side-reactions originate, and what the analytical packet tells you about synthesis quality.
Published April 28, 2026 · 12 min read
Read briefing
QualityHow reverse-phase HPLC methods are developed for peptide analysis, why method development matters more than ready-made protocols, and what an ≥99% purity number really tells you.
Published May 1, 2026 · 11 min read
Read briefing
QualityESI mass spec confirms molecular weight to within 0.5 Da; LC-MS/MS confirms the sequence at the residue level. Why the second test matters for any peptide above 15 residues and what the b/y-ion ladder actually shows.
Published May 3, 2026 · 12 min read
Read briefing
QualityHow peptide stability programs are designed, what accelerated 40°C/75%RH studies do and don't tell you, why some degradation pathways aren't Arrhenius-compliant, and what stability data your COA should show.
Published May 5, 2026 · 11 min read
Read briefing
Industry InsightBPC-157, TB-500, GHK-Cu, Wolverine Blend, B7-33, IGF-1 LR3, MGF, and ARA-290 compared for tissue-repair research. Mechanism, research context, analytical considerations, and how to choose between them.
Published May 7, 2026 · 9 min read
Read briefing
Industry InsightGHK-Cu, Snap-8, Matrixyl, AHK-Cu, Melatonin, Glutathione, and Lipo-C compared for cosmetic and dermal-aesthetic formulation. INCI naming, formulation considerations, regulatory framework, and use-case fit.
Published May 9, 2026 · 10 min read
Read briefing
Industry InsightSemax, Selank, DSIP, Kisspeptin-10, Pinealon, P21, VIP, and PNC-27 compared for cognitive and neuro research. Mechanism, administration route, research evidence, and how to select for specific experimental questions.
Published May 11, 2026 · 10 min read
Read briefing
ComparisonFour most-procured cosmetic peptides compared on mechanism, INCI naming, typical use level, formulation compatibility, and which targets which cosmetic claim. A buyer's decision matrix for OEM brand formulators.
Published May 19, 2026 · 10 min read
Read briefing
ComparisonThree GHRH-receptor agonists compared on engineering, half-life, regulatory pedigree, and best application. Why each occupies a distinct niche despite shared mechanism, and how to choose.
Published May 17, 2026 · 10 min read
Read briefing
ComparisonThree Russian-school cognitive peptides compared on mechanism, indication, administration route, and research evidence. How to choose between BDNF modulation, anxiolytic, and sleep-architecture applications.
Published May 13, 2026 · 9 min read
Read briefing
